AstraZeneca wades deeper into COVID therapeutics
- ByFXEmpire-
LONDON (Reuters) – AstraZeneca has signed a licence agreement with a small UK-based biotech company for a slate of COVID antibody therapies, the Anglo-Swedish pharmaceutical...
Symbol | Exchange | Currency | ||
---|---|---|---|---|
London | GBP | Real-time | ||
London | GBP | Real-time | ||
London | GBP | Real-time | ||
BATS Europe | GBP | Delayed | ||
BATS Europe | SEK | Delayed | ||
NASDAQ | USD | Real-time | ||
OTC Markets | USD | Delayed | ||
Mexico | MXN | Delayed | ||
Stockholm | SEK | Real-time | ||
Frankfurt | EUR | Delayed | ||
TradeGate | EUR | Delayed | ||
Xetra | EUR | Delayed | ||
Frankfurt | EUR | Delayed | ||
Buenos Aires | ARS | Delayed |
LONDON (Reuters) – AstraZeneca has signed a licence agreement with a small UK-based biotech company for a slate of COVID antibody therapies, the Anglo-Swedish pharmaceutical...
By Josh Smith and Hyonhee Shin SEOUL (Reuters) - North Korea is facing its first confirmed COVID-19 outbreak with no known vaccine programme, sparking new calls for the government...
(Reuters) – Investment firm All Blue Capital would be advised by Alan Barge, former oncology head at British drugmaker AstraZeneca Plc, in its bid to acquire drug developer...
Treasury yields rise again, weighing on stocksOil trading above $90US dollar flatKey EventsFutures on the Dow Jones, S&P 500, NASDAQ and Russell 2000 wavered in trading on...
One of the best ways to safeguard investments is by parking money in the healthcare sector. This is because demand for healthcare services does not change with market conditions....
Falling Covid-19 prevalence and widespread vaccinations have boosted confidence in the durability of the recovery. Several data points are at post-pandemic highs and that suggests...
AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Technical Indicators | Buy | Strong Buy | Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
92.65 | 93.88 | 89.52 | +1.49 | +1.63% | 109.00M | NASDAQ | |||
9.97 | 10.10 | 9.31 | +0.58 | +6.18% | 1.91M | NASDAQ | |||
113.20 | 114.93 | 112.35 | -0.57 | -0.50% | 3.17M | NYSE | |||
35.34 | 35.52 | 34.99 | +0.05 | +0.14% | 8.95M | NASDAQ | |||
168.97 | 169.49 | 166.97 | +1.15 | +0.69% | 5.59M | NASDAQ | |||
112.39 | 113.40 | 111.70 | -0.59 | -0.52% | 2.25M | NYSE | |||
4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
8.15 | 8.18 | 7.97 | -0.09 | -1.09% | 4.62M | NYSE | |||
1.135 | 1.15 | 1.11 | +0.0050 | +0.44% | 4.63M | NYSE | |||
39.40 | 39.60 | 38.87 | +0.64 | +1.65% | 5.79M | NYSE | |||
0.1902 | 0.2025 | 0.19 | -0.0178 | -8.56% | 1.43M | NYSE | |||
21.42 | 21.52 | 21.16 | +0.18 | +0.85% | 4.14M | NYSE | |||
32.09 | 32.34 | 30.77 | +1.11 | +3.58% | 5.25M | NYSE | |||
74.44 | 74.59 | 72.65 | -0.08 | -0.11% | 6.99M | NYSE | |||
36.83 | 36.83 | 36.19 | +0.62 | +1.71% | 6.80M | NYSE |